Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma

• Published in: Annals of the rheumatic diseases Vol. 64; no. 6; pp. 958 - 960
• Main Authors: Pijpe, J, van Imhoff, G W, Vissink, A, van der Wal, J E, Kluin, P M, Spijkervet, F K L, Kallenberg, C G M, Bootsma, H
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2005; BMJ; BMJ Publishing Group LTD
• Subjects: Adult; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Biopsy; Concise Report; Exocrine glands; Female; Hematologic and hematopoietic diseases; Humans; Immunomodulators; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphatic system; Lymphoma; Lymphoma, B-Cell, Marginal Zone - drug therapy; MALT lymphoma; Medical sciences; Parotid Gland - immunology; Parotid Gland - physiopathology; Parotid Neoplasms - drug therapy; Pharmacology. Drug treatments; Plasma; Radiation therapy; rheumatoid factor; Rituximab; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Serology; Sjogren's Syndrome - drug therapy; Sjogren's Syndrome - pathology; Sjögren’s syndrome; treatment; Human; Stomatology; Rituximab; Autoimmune disease; Salivary gland; Malignant hemopathy; Monoclonal antibody; Non Hodgkin lymphoma; Sjögren syndrome; Immunomodulator; Eye disease; MALT lymphoma; Lymphoproliferative syndrome; Anticytokine; Systemic disease
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/ard.2004.030684

Objectives: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjögren’s syndrome (SS) and associated MALT lymphoma. Case report: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m2) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow. Discussion: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.